Tags

Type your tag names separated by a space and hit enter

A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia.
Blood 2000; 95(3):1007-13Blood

Abstract

BCR-ABL is a chimeric oncogene generated by translocation of sequences from the chromosomal counterpart (c-ABL gene) on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, BCR-ABL(p190) and BCR-ABL(p210), are produced that are characteristic of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(1)-ALL). In CML, the transformation occurs at the level of pluripotent stem cells. However, Ph(1)-ALL is thought to affect progenitor cells with lymphoid differentiation. Here we demonstrate that the cell capable of initiating human Ph(1)-ALL in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID), termed SCID leukemia-initiating cell (SL-IC), possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all Ph(1)-ALL analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34(+)CD38(-), which is similar to the cell-surface phenotype of normal SCID-repopulating cells. This indicates that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation in Ph(1)-ALL.

Authors+Show Affiliations

Departamento de Proliferación y Diferenciación Celular, Instituto de Microbiología Bioquímica, Universidad de Salamanca, Salamanca, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

10648416

Citation

Cobaleda, C, et al. "A Primitive Hematopoietic Cell Is the Target for the Leukemic Transformation in Human Philadelphia-positive Acute Lymphoblastic Leukemia." Blood, vol. 95, no. 3, 2000, pp. 1007-13.
Cobaleda C, Gutiérrez-Cianca N, Pérez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood. 2000;95(3):1007-13.
Cobaleda, C., Gutiérrez-Cianca, N., Pérez-Losada, J., Flores, T., García-Sanz, R., González, M., & Sánchez-García, I. (2000). A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood, 95(3), pp. 1007-13.
Cobaleda C, et al. A Primitive Hematopoietic Cell Is the Target for the Leukemic Transformation in Human Philadelphia-positive Acute Lymphoblastic Leukemia. Blood. 2000 Feb 1;95(3):1007-13. PubMed PMID: 10648416.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. AU - Cobaleda,C, AU - Gutiérrez-Cianca,N, AU - Pérez-Losada,J, AU - Flores,T, AU - García-Sanz,R, AU - González,M, AU - Sánchez-García,I, PY - 2000/1/29/pubmed PY - 2000/4/29/medline PY - 2000/1/29/entrez SP - 1007 EP - 13 JF - Blood JO - Blood VL - 95 IS - 3 N2 - BCR-ABL is a chimeric oncogene generated by translocation of sequences from the chromosomal counterpart (c-ABL gene) on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, BCR-ABL(p190) and BCR-ABL(p210), are produced that are characteristic of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(1)-ALL). In CML, the transformation occurs at the level of pluripotent stem cells. However, Ph(1)-ALL is thought to affect progenitor cells with lymphoid differentiation. Here we demonstrate that the cell capable of initiating human Ph(1)-ALL in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID), termed SCID leukemia-initiating cell (SL-IC), possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell. The SL-ICs from all Ph(1)-ALL analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34(+)CD38(-), which is similar to the cell-surface phenotype of normal SCID-repopulating cells. This indicates that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation in Ph(1)-ALL. SN - 0006-4971 UR - https://www.unboundmedicine.com/medline/citation/10648416/A_primitive_hematopoietic_cell_is_the_target_for_the_leukemic_transformation_in_human_philadelphia_positive_acute_lymphoblastic_leukemia_ L2 - http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=10648416 DB - PRIME DP - Unbound Medicine ER -